Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H24N4O2.2C2H6O4S |
Molecular Weight | 592.683 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCS(O)(=O)=O.OCCS(O)(=O)=O.NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1
InChI
InChIKey=YBVNFKZSMZGRAD-UHFFFAOYSA-N
InChI=1S/C19H24N4O2.2C2H6O4S/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23;2*3-1-2-7(4,5)6/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23);2*3H,1-2H2,(H,4,5,6)
Molecular Formula | C2H6O4S |
Molecular Weight | 126.132 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H24N4O2 |
Molecular Weight | 340.4195 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB00738
https://en.wikipedia.org/wiki/Pentamidine
Curator's Comment: description was created based on several sources, including:
http://www.drugbank.ca/drugs/DB00738
https://en.wikipedia.org/wiki/Pentamidine
Pentamidine (formulated as a salt, pentamidine diisethionate or dimesilate) is an antimicrobial medication given for prevention and treatment of pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii (formerly known as Pneumocystis carinii), a severe interstitial type of pneumonia often seen in patients with HIV infection. The drug is also the mainstay of treatment for stage I infection with Trypanosoma bruceigambiense (West African trypanosomiasis). Pentamidine is also used as a prophylactic against PCP in patients receiving chemotherapy and in some patients who have undergone organ transplantation, as they also have a depressed immune system as a direct side-effect of the drugs used. The mortality of untreated PCP is very high. Additionally, pentamidine has good clinical activity in treating leishmaniasis, and yeast infections caused by the organism Candida albicans. Pentamidine is also used as a prophylactic antibiotic for children undergoing treatment for leukemia. Studies suggest that the pentamidine isethionate interferes with microbial nuclear metabolism by inhibition of DNA, RNA, phospholipid and protein synthesis. However, the mode of action is not fully understood.
CNS Activity
Sources: http://jpet.aspetjournals.org/content/329/3/967.long
Curator's Comment: Pentamidine is able to cross the BBB, but a proportion is retained within the capillary endothelium. This may well explain its inability to treat well established CNS trypanosome infection. Furthermore, pentamidine movement into the CNS is a complex process involving multiple transporters.
Originator
Sources: https://www.google.ch/patents/EP0315467A2?cl=en
Curator's Comment: Pentamidine was first discovered by Ewins et al., as shown in U.S. Patent No. 2,277,861
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: O14717 Gene ID: 1787.0 Gene Symbol: TRDMT1 Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275129/ |
204.4 µM [EC50] | ||
Target ID: CHEMBL2366046 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | NEBUPENT Approved UsePentamidine Launch Date4.82112012E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
751 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8056699 |
3.9 mg/kg 1 times / day multiple, intravenous dose: 3.9 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PENTAMIDINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
18.8 ng/mL |
4 mg/kg 1 times / day multiple, irrigation dose: 4 mg/kg route of administration: Irrigation experiment type: MULTIPLE co-administered: |
PENTAMIDINE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
612 ng/mL |
4 mg/kg single, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PENTAMIDINE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6734 nM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8056699 |
3.9 mg/kg 1 times / day multiple, intravenous dose: 3.9 mg/kg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
PENTAMIDINE blood | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.4 h |
4 mg/kg single, intravenous dose: 4 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PENTAMIDINE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1600 mg single, intravenous Overdose Dose: 1600 mg Route: intravenous Route: single Dose: 1600 mg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Age Group: 17 Population Size: 1 Sources: |
Other AEs: Impaired renal function, Hepatic impairment... Other AEs: Impaired renal function Sources: Hepatic impairment Hypotension Cardiopulmonary arrest |
600 mg 1 times / month multiple, respiratory Highest studied dose Dose: 600 mg, 1 times / month Route: respiratory Route: multiple Dose: 600 mg, 1 times / month Sources: Page: p.1167 |
unhealthy, 37.9 ± 7.5 n = 76 Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Age Group: 37.9 ± 7.5 Sex: M+F Population Size: 76 Sources: Page: p.1167 |
|
300 mg 1 times / month multiple, respiratory Recommended Dose: 300 mg, 1 times / month Route: respiratory Route: multiple Dose: 300 mg, 1 times / month Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: Page: p.6 |
Disc. AE: Acute pancreatitis... AEs leading to discontinuation/dose reduction: Acute pancreatitis Sources: Page: p.6 |
4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Disc. AE: Hypotension, Hypoglycemia... Other AEs: Extravasation, Injection site ulceration... AEs leading to discontinuation/dose reduction: Hypotension (grade 3-5) Other AEs:Hypoglycemia (grade 5) Acute pancreatitis (grade 5) Cardiac arrhythmias (grade 5) Cardiac arrhythmias (grade 5) Extravasation Sources: Injection site ulceration Injection site necrosis Slough injection site |
4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Disc. AE: Hypotension, Hypoglycemia... Other AEs: Extravasation, Injection site ulceration... AEs leading to discontinuation/dose reduction: Hypotension (grade 3-5) Other AEs:Hypoglycemia (grade 5) Acute pancreatitis (grade 5) Cardiac arrhythmias (grade 5) Cardiac arrhythmias (grade 5) Extravasation Sources: Injection site ulceration Injection site necrosis Slough injection site |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiopulmonary arrest | 1600 mg single, intravenous Overdose Dose: 1600 mg Route: intravenous Route: single Dose: 1600 mg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Age Group: 17 Population Size: 1 Sources: |
|
Hepatic impairment | 1600 mg single, intravenous Overdose Dose: 1600 mg Route: intravenous Route: single Dose: 1600 mg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Age Group: 17 Population Size: 1 Sources: |
|
Hypotension | 1600 mg single, intravenous Overdose Dose: 1600 mg Route: intravenous Route: single Dose: 1600 mg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Age Group: 17 Population Size: 1 Sources: |
|
Impaired renal function | 1600 mg single, intravenous Overdose Dose: 1600 mg Route: intravenous Route: single Dose: 1600 mg Sources: |
unhealthy, 17 n = 1 Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Age Group: 17 Population Size: 1 Sources: |
|
Acute pancreatitis | Disc. AE | 300 mg 1 times / month multiple, respiratory Recommended Dose: 300 mg, 1 times / month Route: respiratory Route: multiple Dose: 300 mg, 1 times / month Sources: Page: p.6 |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: Page: p.6 |
Extravasation | 4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
|
Injection site necrosis | 4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
|
Injection site ulceration | 4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
|
Slough injection site | 4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
|
Hypotension | grade 3-5 Disc. AE |
4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Acute pancreatitis | grade 5 Disc. AE |
4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Cardiac arrhythmias | grade 5 Disc. AE |
4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Cardiac arrhythmias | grade 5 Disc. AE |
4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Hypoglycemia | grade 5 Disc. AE |
4 mg/kg 1 times / day multiple, intramuscular Recommended Dose: 4 mg/kg, 1 times / day Route: intramuscular Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Extravasation | 4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
|
Injection site necrosis | 4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
|
Injection site ulceration | 4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
|
Slough injection site | 4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
|
Hypotension | grade 3-5 Disc. AE |
4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Acute pancreatitis | grade 5 Disc. AE |
4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Cardiac arrhythmias | grade 5 Disc. AE |
4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Cardiac arrhythmias | grade 5 Disc. AE |
4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Hypoglycemia | grade 5 Disc. AE |
4 mg/kg 1 times / day multiple, intravenous Recommended Dose: 4 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Pneumonia due to Pneumocystis carinii Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 0.097 uM] | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. | 1974 Mar |
|
[Kidney failure during treatment of T. rhodesiense trypanosomiasis with pentamidin]. | 1977 |
|
Pentamidine treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Association with acute renal failure and myoglobinuria. | 1985 Dec |
|
Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine. | 1985 Nov 23 |
|
Pentamidine-associated hypotension and route of administration. | 1985 Sep |
|
Pentamidine and renal toxicity. | 1985 Sep 12 |
|
Pentamidine and hematuria. | 1986 Jul |
|
Adverse reactions associated with pentamidine isethionate in AIDS patients: recommendations for monitoring therapy. | 1986 Nov |
|
Torsade de pointes during administration of pentamidine isethionate. | 1987 Sep |
|
Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. | 1988 Aug 15 |
|
Ventricular tachycardia due to pentamidine isethionate. | 1988 May |
|
Torsades de pointes during intravenous pentamidine isethionate therapy. | 1989 Jan 15 |
|
Renal insufficiency with nebulised pentamidine. | 1989 Oct 28 |
|
Nephrotoxicity and hyperkalemia in patients with acquired immunodeficiency syndrome treated with pentamidine. | 1989 Sep |
|
Pentamidine-induced torsades de pointes in a renal transplant recipient with Pneumocystis carinii pneumonia. | 1990 Apr |
|
Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis. | 1990 Jul |
|
Reye's syndrome in adult with AIDS. | 1990 Jun 16 |
|
Ventricular tachycardia and torsades de pointes complicating pentamidine therapy of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. | 1990 Oct 1 |
|
Pentamidine-associated nephrotoxicity and hyperkalemia in patients with AIDS. | 1991 Nov |
|
Anti-cryptosporidial drug activity screened with an immunosuppressed rat model. | 1991 Nov-Dec |
|
Inhibition of topoisomerases from Pneumocystis carinii by aromatic dicationic molecules. | 1991 Nov-Dec |
|
[Infantile visceral leishmaniasis in Morocco. A review of 67 cases managed at the Rabat Hospital for children (1979-1988)]. | 1991 Sep |
|
High pentamidine levels associated with hypoglycemia and azotemia in a patient with Pneumocystis carinii pneumonia. | 1992 Aug |
|
Prolonged recurrence of pentamidine-induced torsades de pointes. | 1992 Nov |
|
Torsade de pointes after inhaled pentamidine. | 1992 Nov |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
A reverse turn structure induced by a D,L-alpha-aminoxy acid dimer. | 2003 Nov 26 |
|
Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia. | 2004 Sep 6 |
|
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. | 2005 Feb |
|
Pentamidine-induced long QT syndrome and block of hERG trafficking. | 2005 Jan |
|
Detection of immunotoxicity using T-cell based cytokine reporter cell lines ("Cell Chip"). | 2005 Jan 15 |
|
Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. | 2005 Oct |
|
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. | 2005 Sep |
|
In vitro selection and in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice. | 2006 Jul |
|
Novel synthesis of nicotinamide derivatives of cytotoxic properties. | 2006 Jul 1 |
|
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. | 2006 Mar |
|
[Cutaneous leishmaniasis--an import from Belize]. | 2007 |
|
Perioral numbness associated with intravenous pentamidine administration. | 2007 Jan |
|
Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis. | 2007 May |
|
Using the zebrafish lateral line to screen for ototoxicity. | 2008 Jun |
|
Pentamidine dosage: a base/salt confusion. | 2008 May 28 |
|
Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs. | 2009 Aug |
|
Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment. | 2009 Jul-Aug |
|
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. | 2010 Dec |
|
Bisbenzamidine derivative, pentamidine represses DNA damage response through inhibition of histone H2A acetylation. | 2010 Feb 9 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
|
The pharmacological profile of brain liver intestine Na+ channel: inhibition by diarylamidines and activation by fenamates. | 2011 Nov |
|
Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives. | 2013 Sep |
|
Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs. | 2015 Jun |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb
Curator's Comment: 300 mg once every four weeks administered via the Respirgard
The recommended adult dosage is 300 mg once every four weeks administered via the Respirgard® II nebulizer. The dose should be delivered until the nebulizer chamber is empty (approximately 30 to 45 minutes). The flow rate should be 5 to 7 liters per minute from a 40 to 50 pounds per square inch (PSI) air or oxygen source. Alternatively, a 40 to 50 PSI air compressor can be used with flow limited by setting the flowmeter at 5 to 7 liters per minute or by setting the pressure at 22 to 25 PSI. Low pressure (less than 20 PSI) compressors should not be used.
Route of Administration:
Irrigation
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/22005072
Pentamidine was found to be active against T. whipplei strains both in axenic medium and in cell culture, with minimum inhibitory concentration ranges of 0.125-0.25mg/L.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:48:54 UTC 2023
by
admin
on
Wed Jul 05 22:48:54 UTC 2023
|
Record UNII |
V2P3K60DA2
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
1083
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
||
|
WHO-ATC |
P01CX01
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
21187
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
3784
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
||
|
FDA ORPHAN DRUG |
25887
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
||
|
NCI_THESAURUS |
C514
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
M8497
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | Merck Index | ||
|
7995
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | RxNorm | ||
|
1504900
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
DTXSID5023796
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
DBSALT000967
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
PENTAMIDINE ISETHIONATE
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | Description: A white, or almost white, crystalline powder; odourless. Solubility: Soluble in 10 parts of water; slightly soluble in ethanol (~750 g/L) TS; practically insoluble in ether R. Category: Antipneumocystosis, antitoxoplasmosis and antitrypanosomal activity. Storage: Pentamidine isetionate should be kept in a well-closed container. Additional information: Pentamidine isetionate is hygroscopic and exhibits polymorphism. Definition: Pentamidine isetionate contains not less than 98.5% and not more than 102.5% of C19H24N4O2,2C2H6O4S, calculatedwith reference to the dried substance. | ||
|
100000079776
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
C29349
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
V2P3K60DA2
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
V2P3K60DA2
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
SUB14795MIG
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
CHEMBL55
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
620107
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
TT-72
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
205-424-1
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
7977
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
757400
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
140-64-7
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY | |||
|
8813
Created by
admin on Wed Jul 05 22:48:54 UTC 2023 , Edited by admin on Wed Jul 05 22:48:54 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |